Sanofi (SNY) Convertible Debt (2020 - 2021)
Sanofi's (SNY) quarterly Convertible Debt came in at $24.4 billion in Q2 2021, down 9.71% quarter-over-quarter from $27.0 billion in Q4 2020.
Sanofi (SNY) Convertible Debt (2020 - 2021) Analysis & Trends
Sanofi has disclosed Convertible Debt across 2 years of filings, most recently posting $24.4 billion for Q2 2021.
- Convertible Debt for Q2 2021 came in at $24.4 billion, changed N/A year-over-year; the trailing twelve-month figure through Jun 2021 was $24.4 billion (changed N/A YoY), and the FY2020 annual result was $25.8 billion, changed N/A from the prior year.
- Convertible Debt came in at $24.4 billion for Q2 2021 at Sanofi, down from $27.0 billion in the prior quarter.
- In the past five years, Convertible Debt ranged from a high of $27.0 billion in Q4 2020 to a low of $24.4 billion in Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn |
| 10 | Sanofi | 59.75 Mn | -6.87 Bn | 9.49 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 24.36 Bn |
| Dec 31, 2020 | 26.98 Bn |